|
by Alex Vasquez, DC, ND
Generally speaking, the
allopathic/pharmaceutical paradigm of anti-inflammatory intervention is
forced to be ineffective and dangerous by the very
nature of the pharmaceutical agents that are relied
upon.
Since the vast majority of drugs are single molecules that intervene at a specific part of a
complex inflammatory phenomena, the end result often is
similar to throwing a monkey wrench into a machine that
is malfunctioning a single aspect of inflammation might be
stopped, but the system continues to malfunction and
might become even more imbalanced as a result of the
so-called "intervention."
Of course, the most recent and most tragic example of this iatrogenesis is the recent Cox-2-inhibitor (coxib) and Vioxx
catastrophe, which injured or killed more than 139,000
Americans.1 Any student of nutritional biochemistry could have anticipated the problems
years before these drugs caused their first deaths and
injuries.2 Indeed, the alarms were sounded within the first few years after the first coxibs were unleashed onto
the "health care" market,3 but these alarms were ignored in favor of the most
aggressive and successful drug-marketing campaign that the world had ever seen one that made celecoxib/Celebrex the most successful drug launch in
U.S. history, with more than 7.4 million prescriptions written within its first
six months.4 The obvious problem with these drugs is that by targeting the Cox-2
enzyme, they block formation of prostacyclin, long considered "the good prostaglandin" due
to its vasodilatory and antithrombotic actions, which are cardioprotective.
Furthermore, any inhibition of cyclooxygenase tends to shunt arachidonic acid into the
formation of leukotrienes, which
promote painless inflammation and the acceleration of
cardiovascular disease.5
The failure of the coxibs exemplifies a major failure of the drug paradigm;
namely that excessive focus on the inhibition of isolated pathways creates additional
imbalance due to its failure to appreciate the multifaceted and interconnected nature
of physiologic systems and biochemical pathways. On the contrary, our holistic
perspective holds that inflammation is most effectively treated by focusing not on
isolated pathways per se, but on the patient's overall health. Using an
effective'overall approach allows specific pathways to be nutritionally supported and modulated,
rather than pharmacologically inhibited. In other words, whereas anti-inflammatory drugs
are specific and inhibitory of normal
function, the natural approach is more
general and supportive of optimal
function.
How can clinicians orchestrate a practical nutritional wellness protocol that
specifically alleviates pain and inflammation? If you've read the first two articles
of this series ("A Five-Part Nutritional Wellness Protocol That Produces
Consistently Positive Results," Sept. 2005, and "Implementing the Five-Part Nutritional
Wellness Protocol for the Treatment of Various Health Problems," Nov. '05), then you
already know how to implement my five-part nutritional wellness protocol, and you
already have a sense for how powerful these basic interventions can be. In essence, we
start by getting the pro-inflammatory junk out of the diet, because we realize that
high-fat and high-carb meals are pro-inflammatory.
Once we've created some space for healthy foods, we encourage consumption
of anti-inflammatory foods such as low-carb, phytonutrient-rich fruits,
vegetables, nuts, seeds and berries. We correct general vitamin and mineral
insufficiencies with a multivitamin and multi-mineral supplement (which provides an
anti-inflammatory benefit6), and we ensure that the daily vitamin D requirement of
3,000-5,000 IU is met by ensuring daily full-body sun exposure or by using a
supplement that provides the appropriate
amount.7 We replace the
health-promoting fatty acids that are missing from the American diet by supplementing with
ALA, GLA, EPA and DHA, and we recommend probiotics to counteract the barrage of
antibiotics that most patients have had to endure during the course of their
viral infections, allergies, and other non-bacterial ailments. Weight loss and the attainment of optimal weight are the natural results of proper diet and
frequent exercise; adipose tissue is inherently
pro-inflammatory,8 and its "replacement" by lean muscle tissue (which is
anti-inflammatory9) helps shift the balance away from inflammation and toward homeostasis and healing. Up to
this point, we merely have turned off the gas lines that were fueling the
inflammatory fire; we have not yet done anything specifically anti-inflammatory per se.
By the time we've re-established the foundation for health, a large percentage
of patients already are healed of their primary ailments, and inflammation and
pain might be reduced significantly.
10
For patients who need additional anti-inflammatory interventions and relief
from pain, now we can begin the implementation of
treatment, which is customized to the needs of the patient. For osteoarthritis, we can use the tried-and-true
glucosamine and purified chondroitin sulfates (note that purified chondroitin sulfate
is cardioprotective11), and now that a study has finally been published on the use
of MSM12 we can be confident that it works, even though we've been using it
successfully for years! For pain associated with inflammation and edema (i.e., recent
injury), proteolytic and pancreatic enzymes work well and work
quickly.13 If we are only treating pain (rather than that which is marked by significant inflammation) we can use
a combination of analgesic botanicals, namely devil's
claw (Harpagophytum
procumbens),14 Willow bark (Salix
spp)15 and Boswellia
serrata.16 If inflammation predominates
over pain, then we might choose to temporarily inhibit NF-kappaB with nutrients and
botanicals such as curcumin17 (requires piperine for absorption in
humans18), lipoic acid,19 green
tea,20 rosemary,21
propolis22 and resveratrol.23,24
Somewhere along the way, when pain and inflammation particularly are severe
or recalcitrant, we need to consider that the inflammation might be being triggered
by an occult or "silent" infection,25,
26 and so we will need to assess and treat
the various foci of dysbiosis.27 Antimicrobial interventions can include
time-released oregano,28,29
berberine,30
artemisinin31,32
hyperforin33 myrrh (Commiphora
molmol),34 bismuth,35 peppermint, uva
ursi,36 thyme,37
clove,38 anise,39
buchu,40 caprylic acid,
dill,41 Brucea
javanica,42 and Acacia
catechu.43 The attainment of anti-rheumatic benefits
via the use of antimicrobial treatments, immunosupportive interventions (rather
than immuno-suppressive drugs), xenobiotic detoxification, and the correction of
hormonal imbalances is the leading edge of anti-inflammatory treatments for autoimmune
diseases and other disorders characterized by severe "idiopathic" inflammation.44
Different health care professions are empowered and disabled by their
respective paradigms, and the merits of each can be contrasted by the results they obtain.
Here in America, drug-centered allopathic medicine, (which mislabels itself
"traditional medicine" even though it has existed for only 60 of the 2.5 million years of
human history) is the third or fourth leading cause of death, responsible for more than
1 million iatrogenic injuries and approximately 180,000 unnecessary deaths per
year.45-47 The American medical system also is the most expensive and inefficient "health
care" system in the world, and it burdens and bankrupts our families, businesses, and
communities48-52 while drug companies enjoy record-breaking multi-billion dollar
profits.53-55 Summarizing the situation in 2000, the Director of World Health
Organization's Global Program on Evidence for Health Policy, Christopher Murray, MD,
PhD,56 concluded, "Basically, you die earlier and spend more time disabled if you're
an American rather than a member of most other advanced countries." In contrast,
a lifestyle of healthy living that includes meditation, yoga, herbal dietary
supplements, and a whole foods diet can reduce total medical expenses by 59% over
four years and by 63% over 11 years compared to patients under "conventional"
medical care; hospital admission rates are reduced 11.4-fold for cardiovascular disease,
3.3-fold for cancer, and 6.7-fold for mental health and substance
abuse.57 The nationwide coverage of chiropractic might save our healthcare system as much as $61 billion
per year58 and would reduce the number of deaths and injuries caused by medical and
surgical treatments.59-61 Thankfully, as the chiropractic profession continues to
increase its scope of practice, more and more Americans will be able to experience
true health without lifelong medicalization with the use of proper diets,
nutritional supplements, and treatments that focus on the cause of the problem, not
merely the symptoms.
References
- Rita Rubin. Scientist says FDA system "broken."
USA Today, Nov. 19, 2004. Click to view it online.
- Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective
COX-2 inhibitors. JAMA 2001;286(8):954-9.
- Topol EJ. Arthritis medicines and cardiovascular events "house of coxibs."
JAMA, Jan. 19, 2005;293(3):366-8.
- Monsanto, Pfizer celebrate Celebrex. St. Louis Business
Journal, July 20, 1999. Click to view it online. Accessed on Jan. 5, 2006.
- Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype,
dietary arachidonic acid, and atherosclerosis. N Engl J
Med, Jan. 1, 2004;350(1):29-37.
- Timms PM, Mannan et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with
VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002;95:787-96.
- Vasquez A, Manso M, Cannell J. The clinical importance of vitamin D (cholecalciferol): a paradigm shift with implications for all
healthcare providers. Alternative Therapies in Health and
Medicine 2004;10:28-37.
http://optimalhealthresearch.com/bionutrition.
- Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue,
adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese
humans. Endocrinology May 2004;145(5):2273-82. Click to view it online.
- Petersen AM, Pedersen BK. The anti-inflammatory effect of
exercise. J Appl Physiol April 2005;98(4):1154-62.
- Vasquez A. Integrative Orthopedics: The Art of Creating Wellness While Effectively Managing Acute
and Chronic Musculoskeletal Disorders.
www.optimalhealthresearch.com.
- Morrison LM, Enrick N. Coronary heart disease: reduction of death rate by chondroitin sulfate
A. Angiology May 1973;24(5):269-87.
- Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF. Efficacy of methylsulfonylmethane (MSM)
in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage, Nov. 22, 2005.
- Vasquez A. Reducing pain and inflammation naturally Part 3: Improving overall health while
safely and effectively treating musculoskeletal pain. Nutritional Perspectives 2005;28:34-38, 40-42. Available
at Click to view it online.
- Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H. Effectiveness of Harpagophytum
extract WS 1531 in the treatment of exacerbation of low-back pain: a randomized, placebo-controlled,
double-blind study. Eur J Anaesthesiol Feb. 1999;16(2):118-29.
- Chrubasik S, Eisenberg E, Balan E, et al. Treatment of low-back pain exacerbations with willow
bark extract: a randomized double-blind study. Am J
Med 2000;109:9-14.
- Kimmatkar N, Thawani V, Hingorani L, Khiyani R. Efficacy and tolerability of Boswellia serrata
extract in treatment of osteoarthritis of knee a randomized double blind placebo controlled trial. Phytomedicine January 2003;10(1):3-7.
- Curcumin, EGCG and resveratrol have been shown to suppress activation of NF-kappa B;
Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of
anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B
activation. Mutat Res, Sept. 1, 2001;480-481:243-68.
- Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in
animals and human volunteers. Planta Med May 1998;64(4):353-6.
- Lee HA, Hughes DA. Alpha-lipoic acid modulates NF-kappaB activity in human monocytic cells
by direct interaction with DNA. Exp
Gerontol, Jan-Mar 2002;37(2-3):401-10.
- Yang F, Oz HS, Barve S, et al. The green tea polyphenols epigallocatechin-3-gallate blocks
nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line
IEC-6. Mol Pharmacol Sept. 2001;60(3):528-33.
- Lo AH, Liang YC, Lin-Shiau SY, Ho CT, Lin JK. Carnosol, an antioxidant in rosemary,
suppresses inducible nitric oxide synthase through down-regulating nuclear factor-kappaB in mouse
macrophages. Carcinogenesis 2002;23(6):983-91.
- Caffeic acid phenethyl ester (CAPE) is an anti-inflammatory component of propolis (honeybee
resin). CAPE is reportedly a specific inhibitor of nuclear factor-kappaB (NF-kappaB);
Fitzpatrick LR, Wang J, Le T. Caffeic acid phenethyl ester, an inhibitor of nuclear factor-kappaB, attenuates bacterial
peptidoglycan polysaccharide-induced colitis in
rats. J Pharmacol Exp Ther, December 2001;299(3):915-20.
- Resveratrol's anticarcinogenic, anti-inflammatory, and growth-modulatory effects may thus be
partially ascribed to the inhibition of activation of NF-kappaB and AP-1 and the associated kinases;
Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear
transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates
and lipid peroxidation. J Immunol, June 15, 2000;164(12):6509-19.
- Both resveratrol and quercetin inhibited NF-kappaB-, AP-1- and CREB-dependent transcription to
a greater extent than the glucocorticosteroid, dexamethasone;
Donnelly LE, Newton R, Kennedy GE, et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol, June 4, 2004 [Epub ahead of print].
- "At the time of initial evaluation, 57 (69%) of the patients with oligoarthritis and 4/20 (20%) of
the control subjects were carriers of clinically silent infections." Weyand CM, Goronzy JJ. Clinically
silent infections in patients with oligoarthritis: results of a prospective study. Ann Rheum Dis February 1992;51(2):253-8.
- Fendler C, Laitko S, Sorensen H, et al. Frequency of triggering bacteria in patients with reactive
arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. Ann Rheum Dis April 2001;60(4):337-43. Click to view it online.
- Vasquez A. Reducing pain and inflammation naturally. Part 6: Nutritional and botanical
treatments against "silent infections" and gastrointestinal dysbiosis, commonly overlooked causes
of neuromusculoskeletal inflammation and chronic health problems. Nutritional Perspectives January 2006; in press.
www.optimalhealthresearch.com/part6.
- Force M, Sparks WS, Ronzio RA. Inhibition of enteric parasites by emulsified oil of oregano in
vivo. Phytother Res May 2000;14(3):213-4.
- Stiles JC, Sparks W, Ronzio RA. The inhibition of Candida albicans by oregano. J Applied Nutr 1995;47:96-102.
- Berberine. Altern Med Rev April 2000;5(2):175-7.
- Dien TK, de Vries PJ, Khanh NX, et al. Effect of food intake on pharmacokinetics of oral artemisinin
in healthy Vietnamese subjects. Antimicrob Agents
Chemother May 1997;41(5):1069-72.
- Giao PT, Binh TQ, Kager PA, et al. Artemisinin for treatment of uncomplicated falciparum malaria:
is there a place for monotherapy? Am J Trop Med
Hyg December 2001;65(6):690-5.
- Schempp CM, Pelz K, Wittmer A, et al. Antibacterial activity of hyperforin from St John's wort,
against multiresistant Staphylococcus aureus and gram-positive bacteria. Lancet, June 19, 1999;353(9170):2129.
- Abo-Madyan AA, Morsy TA, Motawea SM. Efficacy of Myrrh in the treatment of
schistosomiasis (haematobium and mansoni) in Ezbet El-Bakly, Tamyia Center, El-Fayoum Governorate, Egypt. J Egypt Soc Parasitol, August 2004;34(2):423-46.
- Veldhuyzen van Zanten SJ, Sherman PM, Hunt RH. Helicobacter pylori: new developments
and treatments. CMAJ 1997;156(11):1565-74.
- Yarnell E. Botanical medicines for the urinary tract. World J Urol, November 2002;20(5):285-93.
- "...thyme essential oil showed the greatest inhibition against A. hydrophila." Fabio A, Corona A, Forte
E, Quaglio P. Inhibitory activity of spices and essential oils on psychrotrophic bacteria. New Microbiol, January 2003;26(1):115-20.
- Chami N, Chami F, Bennis S, Trouillas J, Remmal A. Antifungal treatment with carvacrol and eugenol
of oral candidiasis in immunosuppressed rats. Braz J Infect
Dis, June 2004;8(3):217-26. www.scielo.br/pdf/bjid/v8n3/21619.pdf.
- "Anise oil was not particularly inhibitory to bacteria (inhibition zone, approximately 25 mm);
however, anise oil was highly inhibitory to molds." Elgayyar M, Draughon FA, Golden DA, Mount JR.
Antimicrobial activity of essential oils from plants against selected pathogenic and saprophytic microorganisms. J Food Prot, July 2001;64(7):1019-24.
- "Buchu preparations are now used as a diuretic and for a wide range of conditions including
stomach aches, rheumatism, bladder and kidney infections and coughs and colds." Simpson D. Buchu South Africa's amazing herbal remedy. Scott Med J December 1998;43(6):189-91.
- Jirovetz L, Buchbauer G, Stoyanova AS, et al. Composition, quality control, and antimicrobial activity
of the essential oil of long-time stored dill (Anethum graveolens L.) seeds from Bulgaria. J Agric Food Chem, June 18, 2003;51(13):3854-7.
- Sawangjaroen N, Sawangjaroen K. The effects of extracts from anti-diarrheic Thai medicinal plants
on the in vitro growth of the intestinal protozoa parasite: Blastocystis hominis. J Ethnopharmacol, April 8, 2005;98(1-2):67-72.
- Rani P, Khullar N. Antimicrobial evaluation of some medicinal plants for their anti-enteric
potential against multi-drug resistant Salmonella typhi. Phytother Res, August 2004;18(8):670-3.
- Vasquez A. Integrative Rheumatology. Click to view it online.
- Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a
meta-analysis of prospective studies. JAMA 1998;279:1200-5.
- Holland EG, Degruy FV. Drug-induced disorders. Am Fam Physician 1997;56(7):1781-8, 1791-2.
- Starfield B. Is U.S. health really the best in the world? JAMA 2000;284(4):483-5.
- "Though the U.S. has slightly fewer doctors per capita than the typical developed nation, we have
almost twice as many MRI machines and perform vastly more angioplasties. At least 31 percent of all
the incremental income we'll earn between 1999 and 2010 will go to health care." Regnier P. Healthcare
myth: We spend too much. Money Magazine. Oct. 13, 2003.
Click to view it online. Accessed July 12, 2004.
- Reinhardt UE, Hussey PS, Anderson GF. U.S. health care spending in an international context. Health Aff (Millwood) 2004;23:10-25.
- Center for Studying Health System Change. Medical Debt a Problem for Almost 20 Million
American Families: Many Face Tough Trade-offs Between Food, Shelter and Medical Care. News Release June
30, 2004. www.hschange.org/CONTENT/690/ Accessed January 4, 2005.
- Hopkins J. Health care tops taxes as small business cost drain. USA Today. Click to view it online. Accessed Jan. 4, 2005.
- A Large Majority of Medicare Beneficiaries Struggle With Low Incomes or Health Problems:
Many Beneficiaries Face Financial Burdens Due To Medical Bills. The Commonwealth Fund. Click to view it online Accessed Jan. 4, 2005.
- Regnier P. Healthcare myth: We spend too much. Money Magazine, Oct 13, 2003. Click to view it online.Accessed Jan. 4, 2005.
- Connolly C. U.S. patients spend more but don't get more, study finds: Even in advantaged
areas, Americans often receive inadequate health care. Washington Post, May 5, 2004; Page A15, Click to view it online Accessed July 28, 2004.
- Angell M. The Truth About the Drug
Companies. Random House; August 2004.
- "Basically, you die earlier and spend more time disabled if you're an American rather than a member
of most other advanced countries." Christopher Murray, MD, PhD, director of the World Health
Organization's Global Program on Evidence for Health Policy Click to view it online Accessed July 12, 2004.
- Orme-Johnson DW, Herron RE. An innovative approach to reducing medical care utilization
and expenditures. Am J Manag Care, January 1997;3(1):135-44.
- Legorreta AP, Metz RD, Nelson CF, et al. Comparative analysis of individuals with and
without chiropractic coverage: patient characteristics, utilization, and costs. Arch Intern Med 2004;164:1985-92.
- Rosner AL. Evidence-based clinical guidelines for the management of acute low-back pain: response
to the guidelines prepared for the Australian Medical Health and Research Council. J Manipulative Physiol Ther 2001;24(3):214-20.
- Dabbs V, Lauretti WJ. A risk assessment of cervical manipulation vs. NSAIDs for the treatment of
neck pain. J Manipulative Physiol Ther 1995;18:530-6.
- Oliphant D. Safety of spinal manipulation in the treatment of lumbar disk herniations: a
systematic review and risk assessment. J Manipulative Physiol
Ther 2004;27:197-210.
Dr. Alex Vasquez began his professional studies at Texas Chiropractic College and later graduated from Western States Chiropractic College in 1996. He then attended the naturopathic medicine program at Bastyr University in Seattle. A complete biography of Dr. Vasquez and a printable version of this article are available online at www.nutritionalwellness.com/columnists/vasquez. |
|
Nutritional Wellness News Update:
|